SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection

Yi-Chun Chen; Sheng-Nan Lu; Huey-Ling You; Chih-Chi Wang; Ing-Kit Lee

doi:10.1001/jamainternmed.2021.7679

SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection

JAMA Intern Med. 2022 Mar 1;182(3):347-349. doi: 10.1001/jamainternmed.2021.7679.

Authors

Yi-Chun Chen¹, Sheng-Nan Lu², Huey-Ling You³, Chih-Chi Wang⁴, Ing-Kit Lee⁵

Affiliations

¹ Division of Infectious Diseases, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
² Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
³ Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
⁴ Department of General Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China.
⁵ School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China.

Abstract

This comparative effectiveness research study compares antibody levels after ChAdOx1 nCoV-19 vaccination in individuals with or without previous SARS-CoV-1 infection.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Viral
Antibody Formation*
COVID-19 / epidemiology
COVID-19 / immunology*
COVID-19 / prevention & control*
ChAdOx1 nCoV-19 / administration & dosage*
China / epidemiology
Female
Humans
Male
Pandemics
SARS-CoV-2
Severe Acute Respiratory Syndrome / immunology*
Severe Acute Respiratory Syndrome / virology*
Severe acute respiratory syndrome-related coronavirus

Substances

Antibodies, Viral
ChAdOx1 nCoV-19